Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 98.50%
March 31, 2026 98.27%
December 31, 2025 98.25%
September 30, 2025 87.85%
June 30, 2025 86.72%
March 31, 2025 86.12%
December 31, 2024 87.41%
September 30, 2024 86.09%
June 30, 2024 85.21%
March 31, 2024 87.57%
December 31, 2023 93.48%
September 30, 2023 87.02%
June 30, 2023 87.24%
March 31, 2023 78.80%
December 31, 2022 66.24%
September 30, 2022 91.15%
June 30, 2022 82.25%
March 31, 2022 91.51%
December 31, 2021 87.48%
September 30, 2021 99.01%
June 30, 2021 77.73%
March 31, 2021 75.82%
December 31, 2020 91.55%
September 30, 2020 81.38%
June 30, 2020 91.00%
Date Value
March 31, 2020 0.00%
December 31, 2019 0.00%
September 30, 2019 0.00%
June 30, 2019 0.00%
March 31, 2019 0.00%
December 31, 2018 0.00%
September 30, 2018 0.00%
June 30, 2018 0.00%
March 31, 2018 0.00%
December 31, 2017 82.71%
September 30, 2017 0.00%
June 30, 2017 0.00%
March 31, 2017 0.00%
December 31, 2016 76.88%
September 30, 2016 74.39%
June 30, 2016 0.00%
March 31, 2016 0.00%
December 31, 2015 0.00%
September 30, 2015 92.44%
June 30, 2015 93.10%
March 31, 2015 0.00%
December 31, 2014 65.11%
September 30, 2014 72.52%
June 30, 2014 89.50%
March 31, 2014 63.02%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Novavax, Inc. 77.70%
Amgen, Inc. 72.08%
BioCryst Pharmaceuticals, Inc. 98.01%
Imunon, Inc. --
Curis, Inc. --

Gross Profit Margin (Quarterly) Related Metrics